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Abstract
Background: The role of small non-coding microRNAs (miRNAs) in several types of cancer has been evident.
However, its expression studies have never been performed in gastric cancer (GC) patients from Saudi population.
First time this study was conducted to identify miRNAs that are differentially expressed in GC patients compared
with normal controls.
Methods: We investigated the role of miRNAs in GC patients using formalin-fixed paraffin-embedded (FFPE) tissues
of 34 samples from GC patients (early stage = 7 and late-stage = 26) and 15 from normal control. We have used
miRNA microarray analysis and validated the results by Real-time quantitative PCR (RT-qPCR).
Results: We obtained data of 1082 expressed genes, from cancer tissues and noncancerous tissues (49 samples
in total). Where 129 genes were up-regulated (P > 0.05) and 953 genes (P > 0.05) were down-regulated in 49 FFPE
tissue samples. Only 33 miRNAs had significant expression in early and late-stage cancer tissues. After candidate
miRNAs were selected, RT-qPCR further confirmed that four miRNAs (hsa-miR-200c-3p, hsa-miR-3613, hsa-miR-27b-
3p, hsa-miR-4668-5p) were significantly aberrant in GC tissues compared to the normal gastric tissues.
Conclusions: In this study we provide miRNAs profile of GC where many miRNAs showed aberrant expression from
normal tissues, suggesting their involvement in the development and progression of gastric cancer. In early and
late-stage miR-200c-3p showed significant down regulation as compare to control samples. Many of miRNAs
reported in our study showing up-regulation are new and not reported before may be due to population
difference. In conclusion, our results suggest that miR-200c-3p had potential to use as diagnostic biomarker for
distinguishing GC patients from normal individuals and can be used for diagnosis of cancer at early stage.
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Background
Gastric Cancer (GC) is the second major cause for
cancer-related deaths worldwide mostly prevalent in
Asian countries, including Korea, Japan and China [1].
In Saudi Arabia, For all cancer types about 2.9 % is
accounted for GC and it is ranked 11th among both male
and female population [2]. Multiple factors contribute to
the progression of gastric tumors, including diet rich in
salted and nitrated food, alcohol consumptions, low
consumption of fruits and vegetables, use of tobacco
and, especially, Helicobacter pylori infection [3]. Like
other malignancies, both genetic and epigenetic factors
are involved in the pathogenesis of gastric cancer [4].
Mortality of the disease is potentially reduces if it is
diagnosed at early stages in gastric cancer [5].
Tumor markers always remain helpful at early stages
in screening of high risks groups. But, the current cancer
tumor markers have limited performance in detection of
gastric cancer due to low sensitivity and specificity [6].
Therefore, it is required to discover some novel diagnostic
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biomarkers for the early detection of this malignancy.
MicroRNAs (miRNAs) are small group of RNA molecules
that regulate expression of different genes by binding to
mRNAs. They play an important role in different cellular
processes that are necessary to maintain a normal phy-
siological condition. In cancer, particular miRNAs act as
tumor supressor or oncogenic hence considered as bio-
markers for early diagnosis and accurate prognosis of
cancer [7]. They are considered to control a variety of func-
tions in tumor cell including cell proliferation, migration,
invasion, differentiation, apoptosis and metabolic processes
[8]. Many previous studies suggest that dysregulated ex-
pression of miRNAs associated with cancers, and function
as tumor inducer and suppressor and their expression may
play an important role in cancer progression. The expres-
sion of miRNAs in different oncogenic pathways suggests
their importance during carcinogenesis [9].
Microarray-based gene expression profiling is a poten-
tial technique to study the expression of miRNAs in GC
patients [10].
Several previous studies have reported that miRNAs
may be used as diagnostic biomarkers in different cancer
types [11]. Fang et al. [12] has suggested some oncogenic
miRNAs (miR-10b, miR-21, miR-223 and miR-338) and
tumor suppressive miRNAs (miR-30a-5p, miR-126 and
let-7a) as prognostic signatures in GC patients. Jiang et
al. [13] has reported higher expression of miR-421 in
early stage GC patients hence suggesting its role as diag-
nostic biomarker in GC. Using miRNA array in GC
patients, abnormal expression of miRNA profiles with
up and down-regulated miRNAs has been reported [14].
Although the importance of miRNAs as important
prognostic factors in patients with GC is confirmed,
but data on the miRNA signature of GC in the Saudi
population is missing. Therefore, the present study
was undertaken to detect the miRNA expression pro-
file of GC patients and normal gastric FFPE tissue
using miRNA 4.0 microarrays. In both early and late
GC tumors, 33 miRNAs were found to be differen-




In this study, 34 gastric cancer tissues samples were
collected from King Abdulaziz University (KAU) hospital
Jeddah. Informed consent was obtained from patients
undergoing a surgical procedure to remove a portion of
gastric cancer. This study was approved by medical
ethical committee of KAU, Jeddah Saudi Arabia (Refer-
ence#174-15). Using the tumor-node-metastasis (TNM)
staging of the International Union Against Cancer
(1997) [15] all the tumor samples were staged and
graded according to the World Health Organization
criteria [16]. From these specimens, we have collected
34 FFPE biopsy samples from gastric cancer patients
and 15 FFPE gastric biopsy samples from healthy in-
dividuals along with detailed clinical history from
KAU hospital (Table. 1).
RNA extraction and quality analysis
RNeasy FFPE kit was used for extraction of RNA from
FFPE tissues according to manufacturer’s instructions.
RNA was further purified using DNase I treatment
(Ambion, Austin, TX) to eliminate any contaminating
DNA. RNA concentrations were calculated using a
Nanodrop ND-1000 spectrophotometer (NanoDrop,
Wilmington, USA). RNA integrity was evaluated by
running electropherograms and RNA integrity number,
RIN (a correlative measure that indicates intactness of
mRNA) was determined using the RNA 6000 PicoAssay
for the Bioanalyzer 2100 (Agilent Technologies, Palo
Alto, USA).
Affymetrix miRNA arrays methods
The Affymetrix Genechip miRNA 4.0 array process was
carried out according to the manufacturer’s instructions.
1000 ng RNA samples were labeled with the FlashTag™
Biotin using RNA Labeling Kit (Genisphere, Hatfield,
PA, USA). The labeled RNA was further quantified, frac-
tionated and hybridized to the miRNA microarray
according to the standard protocol. The labeled RNA
was then heated at 99 °C and then at 45 °C (for 5 mins
at both temp). An Affymetrix® 450 Fluidics Station was
used for RNA-array hybridization with agitation at 60
rotations per minute at 48 °C for 16 h. The chips were
washed and stained using a Genechip Fluidics Station
450 (Affymetrix, Santa Clara, California, United States).
The chips were then scanned with an Affymetrix GCS
3000 canner (Affymetrix, Santa Clara, California, United
States). Using the Affymetrix® GeneChip™ Command
Console software (AGCC) signal values were computed.
Raw data preparation and statistic analysis
Raw data were extracted automatically in Affymetrix
data extraction protocol using the software provided by
AGCC. The CEL files import, miRNA level RMA +
DABG-All analysis and result export using Affymetrix®
Expression Console™ Software. Array data were filtered
by probes annotated species. The comparative analysis
between GC samples and control samples was carried
out using independent T-test and fold-change where the
null hypothesis was that no difference exists among two
groups. False discovery rate (FDR) was further controlled
by the adjustment of p value using Benjamini-Hochberg
algorithm. All Statistical tests and visualization of differ-
entially expressed genes were done using R statistical
language v. 3.1.2.
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MiRNA quantification by real-time quantitative PCR
(RT-qPCR)
For miRNA quantification SYBR Green RT-qPCR assay
was used. Using miScript Reverse Transcription kit (Qia-
gen) one microgram of RNA was reverse-transcribed to
cDNA. Further using miScript SYBR Green PCR kit (Qia-
gen) along with Universal primer and the miRNA-specific
primers qPCR is performed in ABI 7900 Real-time PCR
system (Applied Biosystems). The miRNA-specific primer
sequences were designed using miRNA sequences ob-
tained from the miRBase database. Each reaction mixture
contained 10 μl of 2× Fast SYBR Green Master Mix (Life
Technologies, Grand Island, NY), 0.5 μl of dye (ROX) II
(50x), 1 μl of forward primer, 1 μl of reverse primer, 10 μL
of distilled water, and 1 μl of cDNA template. Each sample
was run in duplicates and U6 miRNA was used as control
to normalize the expression levels of miRNAs. Mean
expression values of each miRNAs (dublicate) relative to
U6 RNA were calculated using the 2-ΔCT method [17],
wherein ΔCt = Ct(tumor)-Ct(control) and control is the sample
without treatment.
Results and discussion
Expression profiles of miRNA in gastric cancer
We used miRNA 4.0 array gene chips, to evaluate
miRNA expression profiles between FFPE GC and
normal tissues. By adjusting average change >2-fold and
value <0.05 as a cut-off level, 1082 expressed genes were
differentially expressed between the cancerous and nor-
mal control. Among them, one-way ANOVA showed
that only 33 miRNAs had significant expression, where 8
(has-mir-193a-5p, has-mir-200c-3p, has-mir-1227-5p,
has-mir-1909-3p, has-mir-1378, has-mir-3613-3p, has-mir-
5196-5p and has-mir-7704) were apparently expressed in
early stage cancer tissues (p < 0.05) and 25 (hsa-miR-22-3p,
hsa-miR-28-3p, hsa-miR-29a-3p, hsa-miR-99a-5p, hsa-miR-
27b-3p, hsa-miR-143-3p, hsa-miR-145-5p, hsa-miR-1251-
5p, hsa-miR-126-3p, hsa-miR-185-5p, hsa-miR-200c-3p,
hsa-miR-130b-3p, hsa-miR-378a-3p, hsa-miR-877-5p, hsa-
miR-128, hsa-miR-378c, hsa-miR-3613-3p, hsa-miR-4532,
Table 1 Clinopathological features of GC patients with
normal control
Sample ID T N M Age Sex Tissue type
Normal
S14-0054 50 Female Normal
S14-0211 40 Female Normal
S14-0267 30 Female Normal
S14-0301 38 Female Normal
S14-0306 31 Female Normal
S12-0959 53 Male Normal
S12-0851 37 Male Normal
S12-0850 31 Female Normal
S12-0710 47 Male Normal
S12-0682 28 Female Normal
S12-0669 36 Female Normal
S12-0447 22 Male Normal
S12-0306 26 Female Normal
S12-0080 32 Male Normal
S12-0049 30 Male Normal
Early-stage
S14.4411 1 0 0 56 Female Cancer
S09-1886 2 0 0 78 Male Cancer
S11-4426 2 0 0 87 Male Cancer
S09-2859 2 0 0 52 Male Cancer
S09-3092 2 0 0 59 Female Cancer
S09-3841 2 0 0 72 Male Cancer
S07-2116 2 0 0 62 Male Cancer
Late-stage
S13.0349-1 3 2 0 53 Male Cancer
S13.0214-4E 3 2 0 47 Male Cancer
S13.3130-1D 4 1 1 59 Male Cancer
S13.3278-1D 3 2 0 70 Female Cancer
S13.5248-2 4 3 1 55 Male Cancer
S14.2777 2 2 0 58 Male Cancer
S14.4235 4 3 1 18 Male Cancer
S14.0190-1 3 2 0 77 Male Cancer
S14.1176-1H 3 2 0 48 Male Cancer
S09-3254 4 3 1 82 Female Cancer
S09-3678 4 1 0 72 Male Cancer
S09-251 3 3 0 57 Male Cancer
S00-1751 2 2 0 55 Male Cancer
S01-658 2 2 0 60 Male Cancer
S02-3330 2 2 0 45 Male Cancer
S02-3307 2 2 0 62 Male Cancer
S02-423 3 3 1 71 Female Cancer
S03-3123 3 3 0 54 Male Cancer
Table 1 Clinopathological features of GC patients with
normal control (Continued)
S06-3929 3 3 0 65 Male Cancer
S06-3390 3 3 0 27 Male Cancer
S06-3357 3 3 0 48 Male Cancer
S06-2460 2 1 0 81 Female Cancer
S06-2397 2 1 0 58 Male Cancer
S06-1949 3 2 0 43 Male Cancer
S06-1939 3 2 0 61 male Cancer
S06-1830 2 2 0 43 Male Cancer
S06-1875 2 2 0 60 Male Cancer
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Table 2 Expression profile of up and down-regulated miRNAs in GC patients
Transcript ID(Array Design) Accession Fold Change (linear) (GC vs. Control) FDR p-value (GC vs. Control)
Detected in early stage (I and II)
hsa-miR-193a-5p MIMAT0004614 −2.06796 0.77052133
hsa-miR-200c-3p MIMAT0000617 −22.552013 0.77052133
hsa-miR-1227-5p MIMAT0022941 −1.717431 0.77052133
hsa-miR-1909-3p MIMAT0007883 −1.951977 0.77052133
hsa-miR-3178 MIMAT0015055 −1.826664 0.72999652
hsa-miR-3613-3p MIMAT0017991 2.981591 0.72999652
hsa-miR-5196-5p MIMAT0021128 −1.959981 0.77052133
hsa-miR-7704 MIMAT0030019 −1.893422 0.72999652
U79 _ 1.738033 0.74726754
Detected in early stage (III and IV)
hsa-miR-22-3p MIMAT0000077 −1.90434 0.10052633
hsa-miR-28-3p MIMAT0004502 −1.87632 0.145678142
hsa-miR-29a-3p MIMAT0000427 −1.96579 0.196109756
hsa-miR-99a-5p MIMAT0000097 −1.97584 0.21331947
hsa-miR-27b-3p MIMAT0000419 −2.29128 0.275381924
hsa-miR-143-3p MIMAT0000435 −2.20679 0.132397944
hsa-miR-145-5p MIMAT0000437 −2.20593 0.271934938
hsa-miR-1251-5p MIMAT0028700 −2.70147 0.014814394
hsa-miR-126-3p MIMAT0005903 −1.9555 0.292936143
hsa-miR-185-5p MIMAT0001339 −1.55828 0.212836342
hsa-miR-200c-3p MIMAT0000455 −2.18027 0.113424849
hsa-miR-130b-3p MIMAT0000691 −2.41458 0.126769698
hsa-miR-378a-3p MIMAT0000732 −1.78021 0.074619747
hsa-miR-877-5p MIMAT0004949 1.696113 0.064059796
hsa-miR-1281 MIMAT0005939 −1.97312 0.064954696
hsa-miR-378c MIMAT0016847 −2.51734 0.016444786
hsa-miR-3613-3p MIMAT0017991 2.507303 0.212235198
hsa-miR-4532 MIMAT0019071 −2.05911 0.046570249
hsa-miR-4668-5p MIMAT0019745 2.097354 0.268773791
hsa-miR-4800-5p MIMAT0019978 1.510005 0.257957349
hsa-miR-6124 MIMAT0024597 2.156251 0.088004364
hsa-miR-6812-5p MIMAT0027524 1.583428 0.250692071
hsa-miR-7150 MIMAT0028211 1.628161 0.277892706
hsa-miR-7704 MIMAT0030019 −1.64036 0.016444786
hsa-miR-7847-3p MIMAT0030422 1.59577 0.244713443
U3 _ 1.780994 0.060093686
U63 _ −1.69859 0.116804752
U3-2B _ 1.761599 0.070969781
U3-2 _ 1.761599 0.070969781
U3-3 _ 1.761599 0.070969781
U3-4 _ 1.761599 0.070969781
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Fig. 1 (a) Comparison of sample distribution using box plot (b) and scatter plot to show difference in miRNAs expression between cancerous
and normal control samples
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hsa-miR-4668-5p, hsa-miR-4800-5p, hsa-miR-6124, hsa-
miR-6812-5p, hsa-miR-7150, hsa-miR-7704, hsa-miR-7847-
3p) were in advanced stage cancer samples as compare to
normal control (p < 0.05) (Table. 2). As we used 2-fold as
cut off value so some aberrant miRNAs in the chip analysis
may be neglected. Differentially expressed genes were re-
lated to signal transduction, metabolism, angiogenesis, cell
structure and cycle, and gene protein expression were
mostly down-regulated. We found 13 new among 33 aber-
rant miRNAs that have not been reported before in GC
studies. These miRNAs named as hsa-miR-1227-5p, hsa-
miR-1909-3p, hsa-miR-3178, hsa-miR-7704 (in early-stage
GC) and hsa-miR-1251-5p, hsa-miR-877-5p, hsa-mir-1281,
hsa-miR-4532, hsa-miR-6124, hsa-miR-6812-5p, hsa-mir-
7150, hsa-mir-7704 and hsa-mir-7847-3p (in late-stage GC)
(Table. 2). There are many concerns about the integrity of
miRNA from FFPE tissues and their suitability for micro-
array as RNA might be modified in chemical reaction and
become fragmented in FFPE tissues [18] but due to very
small size of miRNA (about 19-22 nucleotides) it’s not
degraded in FFPE preparation. Many previous studies of
miRNA microarray supporting a correlation in miRNA ex-
pression results from fresh and FFPE cancer tissues samples
[19–21]. We found in all samples good value of RNA
integrity and optical density (data not shown). In order to
assess miRNA data after filtering we built box plot to
visualize the distribution of data. The distributions of log2
ratios are almost same among miRNA chips. The probe-
level data for the box plots are distributed from about 2–14
on the log scale (Fig. 1a). To check variation between can-
cer and normal tissues samples we assess the data using
scatter-plot. Around 70–80 % miRNA seems to be same in
cancerous and normal tissues used in this study (Fig. 1b).
Identification of differentially expressed miRNAs in early
vs late-stage GC
We analyzed the expression of miRNAs significantly
expressed from cancerous (early and last stage) and
normal tissues using Volcano plot filtering. For up and
down-regulated miRNAs genes we used ≥ 2.0 fold
change and value P value (<0.05). In this plot, differen-
tially expressed genes are statistically significant and are
shown in red and green points (Fig. 2). We identified
1082 differently expressed miRNA and only 33 had sig-
nificant expression, where 9 genes showed up-regulation
and 24 genes showed down-regulation of expression in
GC (early and late-stage GC) as compare to normal
gastric tissues. Further hierarchical clustering analyses
Fig. 2 Volcano plot showing the relative expression of miRNA genes. The vertical lines correspond to 2.0-fold up and down, respectively, and the
horizontal line represents a value of 0.05. The red point in the plot represents the differentially expressed genes with statistical significance
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(Fig. 3) were performed on the basis of differentially
expressed miRNAs from cancerous versus normal tis-
sues. Based on this hierarchical clustering, we have
divided miRNAs expression in three groups: early-stage,
late-stage and normal tissues. These results showed
change in cancerous and control tissue samples. We
have identified many new miRNAs from this study from
Saudi population that have never been reported in stud-
ies related to cancer as well as in GC. Among 33 aber-
rant miRNAs (early and late-stage GC) 13 were new and
rest of the miRNAs were reported before in cancer stud-
ies. Similarly, from remaining 20 miRNAs, only 9 were
reported in GC studies before. Most of the miRNAs
were down-regulated only 9 were up-regulated. In early-
stage GC tissue samples, 8 miRNAs had aberrant
expression as compare to normal control. Among them
7 was up-regulated and only 1 showed down-regulation
(Table. 2). Some of them were not reported before in
GC except has-mir-200c-3p. Some miRNAs identified in
early-stage cancer tissues samples, including hsa-miR-
193a-5p, hsa-miR-3613 and hsa-miR-5196-5p were
reported already in cervical cancer and acute lympho-
blastic leukemia [22, 23]. In our study, significant down-
regulation of has-mir-200c-3p has been seen in early
and late-stage GC tissue samples.
The miR-200 family consists of five members and is
encoded by two genes on chromosomes 12 and function
as tumor regulator [24, 25]. It plays an important role in
different types of cancer by inhibition, invasion, migra-
tion, proliferation and drug resistance. Previous studies
have shown down-regulation of miR-200c in GC that is
consistent with our study [26, 27]. The miR-200c has
Fig. 3 Hierarchical clustering for differentially expressed miRNAs in cancer versus normal pass volcano plot. Red indicates high relative expression
and green indicates low relative expression
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been reported in various types of cancers, including colo-
rectal [28], breast [29], cholangiocarcinoma [30], colorec-
tal [31], hepatocellular [32], lung adenocarcinoma [33],
ovarian [34] and renal cell carcinoma [35]. The miR-200
family inhibits the epithelial-mesenchymal transition and
metastasis by down-regulating ZEB1 and ZEB2 (Zinc-fin-
ger E-box Binding homeobox 1 and 2). The miR-200 in-
hibits angiogenesis by regulating interleukin-8 and CXCL1
secreted by cancer cells. Marked reduction of angiogenesis
has been observed after delivering miR-200 members into
the tumour endothelium [36]. Another study reported
that extracellular matrix proteins and peptidases are tar-
geted by miR-200 and alters the tumor microenvironment
to inhibit metastasis [37]. H. pylori induced infection is
another risk factor for progression of GC. Matsushima et
al. [38] have characterized that decreased expression of
tumor suppressor family miR-200 has been seen in H.pyl-
ori positive GC patients. Few other studies reported
down-regulation of miR-200 in H. pylori-infected GC and
increased expression of anti-apoptotic proteins, Bcl-2 and
XIAP hence inhibiting apoptosis [39–41].
In late-stage GC tissue samples, 8 miRNAs were up-
regulated and 17 showed down-regulation with 10 new
miRNAs (has-mir-1251-5p, has-mir-877-5p, has-mir-1281,
has-mir-378c, has-mir-4532, has-mir-6124, has-mir-6812-
5p, has-mir-7150, has-mir-7704 and has-mir-7847-3p) not
reported before (Table. 2). Many miRNAs involve in
tumorigenesis and altered in variety of cancers are detected
in our study such as tumor-suppressor (has-mir-22-3p,
has-mir-28-3p, has-mir-99a-5p, has-mir-130b-3p, has-mir-
378a-3p, has-mir-3613-3p, has-mir-4668-5p and has-mir-
4800-5p) are reported before in colorectal [42], cervical
[22] and breast cancer [43]. Some of the miRNAs (has-mir-
29a-3p, has-mir-27b-3p, has-mir-143-3p, has-mir-145-5p,
has-mir-126-3p, has-mir-185-5p, has-mir-200c-3p) differ-
ential expressed in late-stage GC samples had similar
kind of expression in previously published GC studies.
The down-regulation of has-miR-29a-3p in our study is
consistent with previous study of GC where decreased
expression of has-miR-29a-3p promotes cell prolifera-
tion by suppressing the expression of cell cycles regula-
tors [44, 45]. The receptor tyrosine kinase like orphan
receptor 1 (ROR1) protein is an oncogenic protein. The
miR-27b-3p suppress the expression of ROR1 in GC
hence function as tumor suppressor [46]. Similar ex-
pression of has-mir-27b-3p has been detected in our
study. Furthermore, other GC related miRNAs such as
has-mir-143-3p, has-mir-145-5p, has-mir-126-3p, has-
mir-185-5p have found to be down-regulated in our
study have shown similar expression in other studies
and reported as tumor-suppressors [47–49]. In addition
to miRNAs, we found seven small nucleolar RNA
(snoRNAs) differentially expressed in both early and
late-stage tumor samples. In our study, only 1 snoRNA
(U63) showed down-regulation and others (U79, U3,
U3-2b, U3-2, U3-3 and U3-4) were up-regulated and
are related to human C/D box group (Table. 2). Several
recent studies have highlighted the role of snoRNAs as
miRNAs precursors and have similar function like miR-
NAs [50, 51]. Another study on Epstein-Barr virus
genome, suggests their role in infection [52]. What role
these snoRNAs may play in GC is interesting to explore.
The present study has limitations due to small number
of tumor samples (n = 34), especially samples of early
stages. Therefore, results of the present study need further
validation using larger group of GC patients in future.
Our results showed that significant down-regulation of
has-mir-200c-3p is markedly observed in early-stage GC
as compare to late-stage GC samples.
Fig. 4 Quantification of the highly expressed miRNAs in the human
GC versus normal control in four selected upregulated miRNA. (a)
Early-stage and (b) Late-stage miRNAs
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Validation of dysregulated miRNAs by quantitative PCR
analysis
Further using real-time quantitative PCR analysis, re-
sults from expression array were validated. We selected
four significantly aberrant miRNAs with 2-fold change
including hsa-miR-200c-3p, hsa-miR-3613, hsa-miR-
27b-3p, hsa-miR-3613 from both stages to test in can-
cerous versus normal tissues and miRNA U6 was used
as control. The miRNA expression analysis of 2 oncogenic
hsa-miR-200c and hsa-miR-27b-3p was significantly
down-regulated while hsa-miR-3613 and hsa-miR-3613
showed up-regulation in comparison with normal control
(Fig. 4a and b) that is consistent with miRNAs array
results. Significantly down-regulation of hsa-miR-200c
has been reported previously in many studies of cancer
indicating the role of hsa-miR-200c as tumor suppres-
sor [24–34]. hsa-miR-200c had multiple roles in regu-
lating tumor cell growth by inhibiting the metastasis
and invasion of hepatocellular carcinoma and gastric
carcinoma [35, 36]. At last, accordant down-regulation
of hsa-miR-200c in GC tissues was detected, in com-
parison with the normal tissues. We also found aber-
rant expression of some new miRNAs in GC patients,
which have no report of aberrant expression in any
other studies.
Conclusions
In conclusion, we explored the miRNAs expression of
FFPE gastric tissues from GC patients and normal control.
Many miRNAs showed aberrant expression in cancerous
versus normal control. As it is evident from many previ-
ous studies and also the current results strongly suggest
that hsa-miR-200c acts as a tumor suppressor miRNA that
plays a potential role in the oncogenesis in humans. Hence
highlighting its functions as a tumor-suppressive miRNA
and prognostic marker in GC patients in Saudi popula-
tion. The significance and role of aberrant miRNAs
expression of GC patients in Saudi population will be bet-
ter understood as more miRNAs will be identified. Our
study may be helpful in future to identify potential prog-
nostic biomarkers for GC.
Abbreviations
GC: Gastric cancer; miRNAs: microRNAs; FFPE: Formalin-fixed paraffin-
embedded; qPCR: Real-time quantitative PCR
Declarations
This article has been published as part of BMC Genomics Volume 17
Supplement 9, 2016: Proceedings of the 3rd International Genomic Medicine
Conference: genomics. The full contents of the supplement are available
online at http://bmcgenomics.biomedcentral.com/articles/supplements/
volume-17-supplement-9.Publication fees for this article are paid by the
Center of Excellence in Genomic Medicine Research (CEGMR), King Abdulaziz
University, Jeddah, Kingdom of Saudi Arabia.
Acknowledgements
This project was funded by the National Plan for Science, Technology
and Innovation (MAARIFAH)–King Abdulaziz City for Science and
Technology-the Kingdom of Saudi Arabia-award number (12-BIO-2725-
03). The authors also, acknowledge with thanks Science and Technol-
ogy Unit, King Abdulaziz University for technical support.
Authors’ contributions
FB and MIN made substantial contributions to design the study. SA, MY,
AMA, MHA and EIA were involved in expression arrays and data
interpretation. AJF and AS were responsible for sample collection and of
clinical databases. FB and MIN drafted the manuscript. All authors read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
This study was approved by the Research Committee of the
Biomedical Ethics Unit, Faculty of Medicine, King Abdulaziz
University, Jeddah, Saudi Arabia.
Author details
1Special Infectious Agents Unit, King Fahd Medical Research Centre, King
Abdulaziz University, Jeddah 21589, Kingdom of Saudi Arabia. 2Center of
Excellence in Genomic Medicine Research (CEGMR), King Abdulaziz
University, Jeddah 21589, Saudi Arabia. 3Department of Medical Laboratory
Technology, Faculty of Applied Medical Sciences, King Abdulaziz University,
Jeddah, Saudi Arabia. 4Department of Medical Microbiology and Parasitology,
Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
5Department of Anatomical Pathology, Faculty of Medicine, King Abdulaziz
University, Jeddah, Saudi Arabia. 6KACST Technology Innovation Center in
Personalized Medicine, King Abdulaziz University, P.O. Box 80216, Jeddah
21589, Kingdom of Saudi Arabia.
Published: 17 October 2016
References
1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer
J Clin. 2005;55(2):74–108.
2. Saudi Cancer Registry. Cancer incidence report in Saudi Arabia 2010. Riyadh
(KSA): Saudi Cancer Registry; 2014. http://www.scr.org.sa/.
3. Mínguez B, Lachenmayer A. Diagnostic and prognostic molecular markers in
hepatocellular carcinoma. Dis Markers. 2011;31(3):181–90.
4. Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ. Gastric cancer.
Lancet. 2009;374(9688):477–90.
5. Gotoda T, Yamamoto H, Soetikno RM. Endoscopic submucosal dissection of
early gastric cancer. J Gastroenterol. 2006;41(10):929–42.
6. Li C, Jian Fang L, Qu C, Qing Qing Q, Min Y, Bing Ya L, Zheng Gang Z.
MiRNA-199a-3p: a potential circulating diagnostic biomarker for early gastric
cancer. J Surg Oncol. 2013;108(2):89–92.
7. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S,
Powers S, Cordon-Cardo C, et al. A microRNA polycistron as a potential
human oncogene. Nature. 2005;435(7043):828–33.
8. Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D, Diehn M, Liu H,
Panula SP, Chiao E, Dirbas FM. Downregulation of miRNA-200c links breast
cancer stem cells with normal stem cells. Cell. 2009;138(3):592–603.
9. Yao Y, Suo AL, Li ZF, Liu LY, Tian T, Ni L, Zhang WG, Nan KJ, Song TS,
Huang C. MicroRNA profiling of human gastric cancer. Mol Med Report.
2009;2(6):963–70.
10. Jiang HB, Yang TJ, Lu P, Ma YJ. Gene expression profiling of gastric cancer.
Eur Rev Med Pharmacol Sci. 2014;18(15):2109–15.
11. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev
Cancer. 2006;6(11):857–66.
12. Fang Y, Shen H, Li H, Cao Y, Qin R, Long L, Zhu X, Xie C, Xu W. miR-106a
confers cisplatin resistance by regulating PTEN/Akt pathway in gastric
cancer cells. Acta Biochim Biophys Sin. 2013;45(11):963–72.
13. Jiang Z, Guo J, Xiao B, Miao Y, Huang R, Li D, Zhang Y. Increased
expression of miR-421 in human gastric carcinoma and its clinical
association. J Gastroenterol. 2010;45(1):17–23.
The Author(s) BMC Genomics 2016, 17(Suppl 9):751 Page 59 of 87
14. Li X, Luo F, Li Q, Xu M, Feng D, Zhang G, Wu W. Identification of new
aberrantly expressed miRNAs in intestinal-type gastric cancer and its clinical
significance. Oncol Rep. 2011;26(6):1431–9.
15. Sobin LH, Wittekind CH. TNM classification of malignant tumors. 5th ed.
New York: Wiley; 1997. p. 59–62.
16. Solcia E, Capella C. Endocrine tumours of the gastrointestinal tract. In: Solcia
E, Kloppel G, Sobin LH, editors. Histological typing of endocrine tumours.
2nd ed. Berlin: Springer; 2000. p. 61–8.
17. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using
real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods.
2001;25:402–8.
18. Liu A, Xu X. MicroRNA isolation from formalin-fixed, paraffin-embedded
tissues. Methods Mol Biol. 2011;724:259–67.
19. Li J, Smyth P, Flavin R, Cahill S, Denning K, Aherne S, Guenther SM, O’Leary
JJ, Sheils O. Comparison of miRNA expression patterns using total RNA
extracted from matched samples of formalin-fixed paraffin-embedded
(FFPE) cells and snap frozen cells. BMC Biotechnol. 2007;7:36.
20. Glud M, Klausen M, Gniadecki R, Rossing M, Hastrup N, Nielsen FC,
Drzewiecki KT. MicroRNA expression in melanocytic nevi: the usefulness of
formalin-fixed, paraffin-embedded material for miRNA microarray profiling.
J Invest Dermatol. 2009;129(5):1219–24.
21. Zhang X, Chen J, Radcliffe T, LeBrun DP, Tron VA, Feilotter H. An array-based
analysis of microRNA expression comparing matched frozen and formalin-
fixed paraffin-embedded human tissue samples. J Mol Diagn. 2008;10(6):513–9.
22. Lui WO, Pourmand N, Patterson BK, Fire A. Patterns of known and novel
small RNAs in human cervical cancer. Cancer Res. 2007;67(13):6031–43.
23. Schotte D, Moqadam FA, Lange-Turenhout EAM, Chen C, Van IJcken WFJ,
Pieters R, Den Boer ML. Discovery of new microRNAs by small RNAome
deep sequencing in childhood acute lymphoblastic leukemia. Leukemia.
2011;25(9):1389–99.
24. Tang H, Deng M, Tang Y, Xie X, Guo J, Kong Y, Ye F, Su Q, Xie X. miR-200b
and miR-200c as prognostic factors and mediators of gastric cancer cell
progression. Clin Cancer Res. 2013;19(20):5602–12.
25. Humphries B, Yang C. The microRNA-200 family: small molecules with novel
roles in cancer development, progression and therapy. Oncotarget. 2015;
6(9):6472.
26. Valladares-Ayerbes M, Reboredo M, Medina-Villaamil V, Iglesias-Díaz P,
Lorenzo-Patiño MJ, Haz M, Santamarina I, Blanco M, Fernández-Tajes J,
Quindós M, Carral A. Circulating miR-200c as a diagnostic and prognostic
biomarker for gastric cancer. J Transl Med. 2012;10(1):186.
27. Feng X, Wang Z, Fillmore R, Xi Y. MiR-200, a new star miRNA in human
cancer. Cancer Lett. 2014;344(2):166–73.
28. Liu L, Qiu M, Tan G, Liang Z, Qin Y, Chen L, Chen H, Liu J. miR-200c Inhibits
invasion, migration and proliferation of bladder cancer cells through down-
regulation of BMI-1 and E2F3. J Transl Med. 2014;12(1):305.
29. Song C, Liu LZ, Pei XQ, Liu X, Yang L, Ye F, Xie X, Chen J, Tang H. miR-200c
inhibits breast cancer proliferation by targeting KRAS. Oncotarget. 2015;
6(33):34968–78.
30. Peng F, Jiang J, Yu Y, Tian R, Guo X, Li X, Shen M, Xu M, Zhu F, Shi C, Hu J.
Direct targeting of SUZ12/ROCK2 by miR-200b/c inhibits cholangiocarcinoma
tumourigenesis and metastasis. Br J Cancer. 2013;109(12):3092–104.
31. Sun J, Ding W, Zh, J, Chen W. MiR-200 suppresses metastases of colorectal
cancer through ZEB1. Tumour Biol. 2015; 1-7
32. Yeh TS, Wang F, Chen TC, Yeh CN, Yu MC, Jan YY, Chen MF. Expression
profile of microRNA-200 family in hepatocellular carcinoma with bile duct
tumor thrombus. Ann Surg. 2014;259(2):346–54.
33. Roybal JD, Zang Y, Ahn YH, Yang Y, Gibbons DL, Baird BN, Alvarez C,
Thilaganathan N, Liu DD, Saintigny P, Heymach JV. miR-200 inhibits lung
adenocarcinoma cell invasion and metastasis by targeting Flt1/VEGFR1. Mol
Cancer Res. 2011;9(1):25–35.
34. Hu X, Macdonald DM, Huettner PC, Feng Z, El Naqa IM, Schwarz JK,
Mutch DG, Grigsby PW, Powel SN, Wang X. A miR-200 microRNA
cluster as prognostic marker in advanced ovarian cancer. Gynecol
Oncol. 2009;114(3):457–64.
35. Nakada C, Matsuura K, Tsukamoto Y, Tanigawa M, Yoshimoto T, Narimatsu T,
Nguyen LT, Hijiya N, Uchida T, Sato F, Mimata H. Genome‐wide microRNA
expression profiling in renal cell carcinoma: significant down‐regulation of
miR‐141 and miR‐200c. J Pathol. 2008;216(4):418–27.
36. Pecot CV, Rupaimoole R, Yang D, Akbani R, Ivan C, Lu C, Wu S, Han HD,
Shah MY, Rodriguez-Aguayo C, Bottsford-Miller J. Tumour angiogenesis
regulation by the miR-200 family. Nat Commun. 2013;4:2427.
37. Schliekelman MJ, Gibbons DL, Faca VM, Creighton CJ, Rizvi ZH, Zhang Q,
Wong CH, Wang H, Ungewiss C, Ahn YH, Shin DH. Targets of the tumor
suppressor miR-200 in regulation of the epithelial-mesenchymal transition
in cancer. Cancer Res. 2011;71(24):7670–82.
38. Matsushima K, Isomoto H, Inoue N, Nakayama T, Hayashi T, Nakayama M,
Nakao K, Hirayama T, Kohno S. MicroRNA signatures in helicobacter pylori-
infected gastric mucosa. Int J Cancer. 2011;128(2):361–70.
39. Furukawa-Hibi Y, Yoshida-Araki K, Ohta T, Ikeda K, Motoyama N. FOXO
forkhead transcription factors induce G(2)-M checkpoint in response to
oxidative stress. J Biol Chem. 2002;277:26729–32.
40. Guttilla IK, White BA. Coordinate regulation of FOXO1 by miR-27a, miR-96,
and miR-182 in breast cancer cells. J Biol Chem. 2009;284:23204–16.
41. Zhu W, Xu H, Zhu D, Zhi H, Wang T, Wang J, Jiang B, Shu Y, Liu P. miR-200bc/
429 cluster modulates multidrug resistance of human cancer cell lines by
targeting BCL2 and XIAP. Cancer Chemother Pharmacol. 2012;69:723–31.
42. Almeida MI, Nicoloso MS, Zeng L, Ivan C, Spizzo R, Gafà R, Xiao L, Zhang X,
Vannini I, Fanini F, Fabbri M. Strand-specific miR-28-5p and miR-28-3p have
distinct effects in colorectal cancer cells. Gastroenterology. 2012;142(4):886–96.
43. Persson H, Kvist A, Rego N, Staaf J, Vallon-Christersson J, Luts L, Loman N,
Jonsson G, Naya H, Hoglund M, Borg A. Identification of new microRNAs in
paired normal and tumor breast tissue suggests a dual role for the ERBB2/
Her2 gene. Cancer Res. 2011;71(1):78–86.
44. Zhao Z, Wang L, Song W, Cui H, Chen G, Qiao F, Hu J, Zhou R, Fan H.
Reduced miR-29a-3p expression is linked to the cell proliferation and cell
migration in gastric cancer. World J Surg Oncol. 2015;13(1):1.
45. Cui Y, Su WY, Xing J, Wang YC, Wang P, Chen XY, Shen ZY, Cao H, Lu YY, Fang
JY. MiR-29a inhibits cell proliferation and induces cell cycle arrest through the
downregulation of p42.3 in human gastric cancer. PLoS One. 2011;6(10):e25872.
46. Tao J, Zhi X, Zhang X, Fu M, Huang H, Fan Y, Guan W, Zou C. miR-27b-3p
suppresses cell proliferation through targeting receptor tyrosine kinase like
orphan receptor 1 in gastric cancer. J Exp Clin Cancer Res. 2015;34(1):1.
47. Xing X, Li Z. Expression of miR-143 and miR-145 and their functional study
in gastric carcinoma. Chinese J Gastrointest Surg. 2015;18(1):50–3.
48. Feng R, Chen X, Yu Y, Su L, Yu B, Li J, Cai Q, Yan M, Liu B, Zhu Z. miR-126
functions as a tumour suppressor in human gastric cancer. Cancer Lett.
2010;298(1):50–63.
49. Tan Z, Jiang H, Wu Y, Xie L, Dai W, Tang H, Tang S. miR-185 is an
independent prognosis factor and suppresses tumor metastasis in gastric
cancer. Mol Cell Biochem. 2014;386(1-2):223–31.
50. Brameier M, Herwig A, Reinhardt R, Walter L, Gruber J. Human box C/D
snoRNAs with miRNA like functions: expanding the range of regulatory
RNAs. Nucleic Acids Res. 2011;39:675–86.
51. Saraiya AA, Wang CC. snoRNA, a novel precursor of microRNA in Giardia
lamblia. PLoS Pathog. 2008;4:e1000224.
52. Hutzinger R, Feederle R, Mrazek J, Schiefermeier N, Balwierz PJ, et al.
Expression and processing of a small nucleolar RNA from the Epstein-Barr
virus genome. PLoS Pathog. 2009;5:e1000547.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
The Author(s) BMC Genomics 2016, 17(Suppl 9):751 Page 60 of 87
